148 related articles for article (PubMed ID: 14550956)
1. Low expression of sodium iodide symporter identifies aggressive thyroid tumors.
Ward LS; Santarosa PL; Granja F; da Assumpção LV; Savoldi M; Goldman GH
Cancer Lett; 2003 Oct; 200(1):85-91. PubMed ID: 14550956
[TBL] [Abstract][Full Text] [Related]
2. The sodium iodide symporter: its pathophysiological and therapeutic implications.
Spitzweg C; Morris JC
Clin Endocrinol (Oxf); 2002 Nov; 57(5):559-74. PubMed ID: 12390328
[TBL] [Abstract][Full Text] [Related]
3. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer.
Ringel MD; Anderson J; Souza SL; Burch HB; Tambascia M; Shriver CD; Tuttle RM
Mod Pathol; 2001 Apr; 14(4):289-96. PubMed ID: 11301345
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas.
Saito T; Endo T; Kawaguchi A; Ikeda M; Katoh R; Kawaoi A; Muramatsu A; Onaya T
J Clin Invest; 1998 Apr; 101(7):1296-300. PubMed ID: 9525971
[TBL] [Abstract][Full Text] [Related]
5. Expression and correlation of sodium/iodide symporter and thyroid stimulating hormone receptor in human thyroid carcinoma.
Wang ZF; Liu QJ; Liao SQ; Yang R; Ge T; He X; Tian CP; Liu W
Tumori; 2011; 97(4):540-6. PubMed ID: 21989446
[TBL] [Abstract][Full Text] [Related]
6. Post-translational Regulation of Radioactive Iodine Therapy Response in Papillary Thyroid Carcinoma.
Amit M; Na'ara S; Francis D; Matanis W; Zolotov S; Eisenhaber B; Eisenhaber F; Weiler Sagie M; Malkin L; Billan S; Charas T; Gil Z
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 30053080
[TBL] [Abstract][Full Text] [Related]
7. Expressions of human sodium iodide symporter mRNA in primary and metastatic papillary thyroid carcinomas.
Park HJ; Kim JY; Park KY; Gong G; Hong SJ; Ahn IM
Thyroid; 2000 Mar; 10(3):211-7. PubMed ID: 10779135
[TBL] [Abstract][Full Text] [Related]
8. Expression pattern of the pendrin and sodium/iodide symporter genes in human thyroid carcinoma cell lines and human thyroid tumors.
Arturi F; Russo D; Bidart JM; Scarpelli D; Schlumberger M; Filetti S
Eur J Endocrinol; 2001 Aug; 145(2):129-35. PubMed ID: 11454507
[TBL] [Abstract][Full Text] [Related]
9. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
[TBL] [Abstract][Full Text] [Related]
10. Sodium-iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas.
Arturi F; Russo D; Giuffrida D; Schlumberger M; Filetti S
Eur J Endocrinol; 2000 Nov; 143(5):623-7. PubMed ID: 11078986
[TBL] [Abstract][Full Text] [Related]
11. Association of low sodium-iodide symporter messenger ribonucleic acid expression in malignant thyroid nodules with increased intracellular protein staining.
Sodré AK; Rubio IG; Galrão AL; Knobel M; Tomimori EK; Alves VA; Kanamura CT; Buchpiguel CA; Watanabe T; Friguglietti CU; Kulcsar MA; Medeiros-Neto G; Camargo RY
J Clin Endocrinol Metab; 2008 Oct; 93(10):4141-5. PubMed ID: 18628528
[TBL] [Abstract][Full Text] [Related]
12. The importance of sodium/iodide symporter (NIS) for thyroid cancer management.
Carvalho DP; Ferreira AC
Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):672-82. PubMed ID: 17891230
[TBL] [Abstract][Full Text] [Related]
13. Predictive role of nontumoral sodium iodide symporter activity and preoperative thyroid characteristics in remission process of thyroid cancer patients.
Yildirim-Poyraz N; Yazgan A; Ozdemir E; Gozalan A; Keskin M; Ersoy R; Turkolmez S; Cakir B
Ann Nucl Med; 2014 Aug; 28(7):623-31. PubMed ID: 24823701
[TBL] [Abstract][Full Text] [Related]
14. Use of sodium iodide symporter expression in differentiated thyroid carcinomas.
Morari EC; Marcello MA; Guilhen AC; Cunha LL; Latuff P; Soares FA; Vassallo J; Ward LS
Clin Endocrinol (Oxf); 2011 Aug; 75(2):247-54. PubMed ID: 21521301
[TBL] [Abstract][Full Text] [Related]
15. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma.
Min JJ; Chung JK; Lee YJ; Jeong JM; Lee DS; Jang JJ; Lee MC; Cho BY
Eur J Nucl Med; 2001 May; 28(5):639-45. PubMed ID: 11383871
[TBL] [Abstract][Full Text] [Related]
16. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.
Schmohl KA; Dolp P; Schug C; Knoop K; Klutz K; Schwenk N; Bartenstein P; Nelson PJ; Ogris M; Wagner E; Spitzweg C
Thyroid; 2017 Dec; 27(12):1534-1543. PubMed ID: 29032724
[TBL] [Abstract][Full Text] [Related]
17. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells.
Schmutzler C; Winzer R; Meissner-Weigl J; Köhrle J
Biochem Biophys Res Commun; 1997 Nov; 240(3):832-8. PubMed ID: 9398654
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake.
Castro MR; Bergert ER; Goellner JR; Hay ID; Morris JC
J Clin Endocrinol Metab; 2001 Nov; 86(11):5627-32. PubMed ID: 11701745
[TBL] [Abstract][Full Text] [Related]
19. Differential regulation of the human sodium/iodide symporter gene promoter in papillary thyroid carcinoma cell lines and normal thyroid cells.
Kogai T; Hershman JM; Motomura K; Endo T; Onaya T; Brent GA
Endocrinology; 2001 Aug; 142(8):3369-79. PubMed ID: 11459780
[TBL] [Abstract][Full Text] [Related]
20. Sodium iodide symporter and pendrin expression in human thyroid tissues.
Mian C; Lacroix L; Alzieu L; Nocera M; Talbot M; Bidart JM; Schlumberger M; Caillou B
Thyroid; 2001 Sep; 11(9):825-30. PubMed ID: 11575851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
